Medication info
Myungmoon Rosuvastatin Calcium Tablet 5 Milligrams

Myungmoon Rosuvastatin Calcium Tablet 5 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Myungmoon Pharmaceutical Co., Ltd.
Appearance
Yellow round film-coated tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201400423 · Approved 2014.01.29 · Insurance code 649806430

Summary

Main use
Improvement of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression
Who takes it
Adults
Adult dose
1. Primary hypercholesterolemia (type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug, and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted as a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased up to a maximum of 20 mg daily. 2. Older adults: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this drug to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this drug is contraindicated in some of these patients.

Ingredients

Manufacturer
Myungmoon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression

  • Primary hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of premature coronary artery disease.
View approved original text

This medication is primarily used in patients with hypercholesterolemia and dyslipidemia. It is used as an adjunct to diet in patients with primary hypercholesterolemia (type IIa) and mixed dyslipidemia (type IIb) that cannot be controlled through diet and exercise alone. Furthermore, it helps patients with homozygous familial hypercholesterolemia alongside other lipid-lowering therapies. This drug is effective in lowering total cholesterol and LDL cholesterol levels, delaying the progression of atherosclerosis. It is also used as an adjunct to diet in patients with primary dysbetalipoproteinemia (type III) and helps reduce the risk of stroke, myocardial infarction, and arterial revascularization in elderly patients at high risk of cardiovascular disease. Thus, it is effectively used for various lipid-related disorders and cardiovascular risk reduction.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug, and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted as a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased up to a maximum of 20 mg daily. 2. Older adults: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this drug to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this drug is contraindicated in some of these patients.

Precautions

This drug should not be administered to certain patients. For instance, it should be avoided in patients who are allergic to this medication, those with active liver disease, patients with muscle disorders, patients with severely impaired kidney function, women who are pregnant or breastfeeding, and when taken with certain medications. Additionally, this drug should be used cautiously in patients with compromised liver function or those who consume large amounts of alcohol, and liver function tests should be performed prior to and during treatment. If symptoms such as muscle pain or weakness occur, notify healthcare providers immediately, and if necessary, conduct blood tests to check for muscle damage. This medication should be used with particular caution in patients at higher risk of muscle damage, such as those with moderate to severe kidney impairment, hypothyroid patients, individuals with a history of muscle disorders, elderly patients, and individuals with alcohol use disorder. This drug contains lactose, so it should not be taken by patients with lactose intolerance, and women of childbearing age should use appropriate contraception. It is safe to avoid this medication during pregnancy. While taking this medication, abnormal symptoms such as liver dysfunction, muscle issues, or allergic reactions may arise, so if these occur, consult healthcare providers immediately. Moreover, this drug can interact with multiple medications, so inform healthcare providers of any other medications being taken, particularly when taken alongside drugs that may increase the risk of muscle damage. In the case of overdose, as no specific antidote exists, seek immediate medical care for proper treatment and examination. Dizziness may occur when operating a vehicle or machinery, so caution is advised, and regular health check-ups and monitoring of symptoms are important while taking this medication.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, hives, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, shortness of breath, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lichenoid drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, discomfort in the chest, loss of appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to prevent exposure to air and moisture, and keep at room temperature between 1 to 30 degrees Celsius. Proper storage will maintain the drug's efficacy and prevent deterioration.

Appearance and packaging

Appearance

Yellow round film-coated tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.